



Article

New *N*-Heterocyclic Carbene Gold and Platinum Complexes with 1,3-Dialkyl-4-anisyl-5-(4-chlorophenyl)imidazol-2-ylidene Ligands for the Treatment of Esophageal Adenocarcinoma

Hindole Ghosh ¹, Tobias Rehm ², Sangita Bhattacharyya ¹, Miru Lee ¹, Dileepkumar Veeragoni ¹ ,
Rainer Schobert ² , Bernhard Biersack ^{2,*} and Prasad Dandawate ^{1,*}

¹ Cancer Biology, University of Kansas Medical Center, 3901 Rainbow Boulevard, Kansas City, KS 66160, USA; mirulee375@gmail.com (M.L.)

² Organic Chemistry 1, University of Bayreuth, Universitätsstrasse 30, 95440 Bayreuth, Germany

* Correspondence: bernhard.biersack@yahoo.com (B.B.); pdandawate@kumc.edu (P.D.)

Abstract

Encouraged by the promising anticancer activity of a iodo-gold(I)-*N*-heterocyclic carbene (NHC) complex with a 1,3-diethyl-4-anisyl-5-(4-chlorophenyl)imidazol-2-ylidene ligand system, a series of new gold(I), gold(III) and platinum(II) complexes coordinated to this ligand system were designed, prepared, and characterized using NMR spectroscopy and mass spectrometry methods. A preliminary anticancer screening of the complexes using four esophageal adenocarcinoma (EAC) cell lines showed promising activities for the cationic triphenylphosphino-NHC-gold(I) and bis-NHC-gold(I) complexes, accompanied by strong antiproliferative, colony-, and spheroid-forming inhibitory effects. The compounds were relatively less toxic to the normal esophageal cell line Het-1A and the monocyte cell line THP-1. Moreover, these compounds induced caspase 3/7 activity and downregulated anti-apoptotic proteins (Bcl-XL, Bcl-2, and Mcl-1) in EAC cells. Further, the cell cycle promoter cyclin D1 was suppressed by these NHC-gold(I) complexes. Finally, we observed strong reactive oxygen species (ROS) induction in EAC cells with NHC-gold(I) complexes **8** and **11**.

Keywords: gold; platinum; carbene ligands; metal-based drugs; anticancer agents; esophageal adenocarcinoma; thioredoxin reductase

1. Introduction

Gold compounds, including the gold(I) complex auranofin, are clinically applied for the therapy, aka chrysotherapy, of chronic inflammatory diseases such as rheumatoid arthritis (Figure 1) [1]. In preclinical experiments, auranofin also exhibited anticancer activity, mainly attributed to its potent inhibition of thioredoxin reductase (TrxR), leading to the formation of toxic reactive oxygen species (ROS) and the induction of apoptosis [1]. The mitochondrial protein import machinery includes the protein Mia40, which was identified as a target of auranofin in fungi and which can play a vital role in proliferating cells [2,3]. A significant proteasomal deubiquitinase (DUB) inhibition was also observed in cancer cells treated with auranofin [4,5]. Moreover, several clinical trials were launched with auranofin for the therapy of various cancers, including CLL, glioblastoma, lung, and ovarian cancer [6]. Consequently, the sound anticancer activities of auranofin prompted the development of improved auranofin derivatives and the design of suitable combination



Academic Editor: Roberto Scatena

Received: 31 December 2025

Revised: 10 February 2026

Accepted: 18 February 2026

Published: 21 February 2026

Copyright: © 2026 by the authors.

Licensee MDPI, Basel, Switzerland.

This article is an open access article

distributed under the terms and

conditions of the [Creative Commons](#)

[Attribution \(CC BY\)](#) license.

therapies of auranofin with other anticancer drugs [7–9]. In addition, neutral and cationic *N*-heterocyclic carbene (NHC) gold complexes exhibited strong anticancer activity, which was attributed in part to TrxR inhibition and to other mechanisms such as DNA binding (e.g., interaction with G-quadruplexes), p53-dependent apoptosis induction, and immunogenic cell death [10–14]. Our groups focused on the effects of NHC-gold complexes with 4,5-diarylimidazole-2-ylidene ligands, inspired by the natural tubulin-binding *cis*-stilbene, combretastatin A-4, on vital cytoskeletal components such as microtubules and actin filaments [15,16]. Notably, considerable damage to the actin cytoskeleton in cancer cells was also observed upon treatment with auranofin [17].





Figure 1. Structures of auranofin, the iodogold(I)-NHC complex **1a**, and the NHC-platinum(II) complexes **1b** and **1c**.

Esophageal cancer (EC) is a therapeutically challenging cancer disease and is globally ranked sixth in mortality (544,076 deaths) and seventh in incidence (604,100 new cases) [18,19]. Case numbers of esophageal adenocarcinoma (EAC) are rising rapidly in high-income countries, associated with lifestyle factors such as obesity, gastroesophageal reflux disease (GERD), and Barrett’s esophagus (BE) [20]. Surgery and chemoradiotherapy with the well-established anticancer platinum(II) complex cisplatin are currently used to treat EC [21]. Promising data in EC patients underscored the relevance of platinum drugs in combination with immune checkpoint inhibitors [22]. Gold complexes might also become suitable drugs for the therapy of EAC, and auranofin was reported to be active against EC [23].

Our group has recently disclosed a new iodogold-NHC (*N*-heterocyclic carbene) complex **1a** with the 1,3-diethyl-4-anisyl-5-(4-chlorophenyl)imidazol-2-ylidene ligand, which exhibited superior activity against esophageal adenocarcinoma (EAC) cells (Figure 1) [24]. Moreover, we have reported platinum(II)-NHC complexes such as **1b** and **1c** with activity against various tumor cell lines (Figure 1) [25]. In the current work, we focused on the design of new analogous complexes of the gold(I)-NHC (**5**, **6**, **8**, **11**, and **12**), gold(III)-NHC (**13**), and platinum(II)-NHC type (**15**) coordinated with the promising 1,3-dialkyl-4-anisyl-5-(4-chlorophenyl)imidazol-2-ylidene ligand system (Scheme 1). Their anticancer potential was analyzed in EAC cell lines. The most promising complexes, **8** and

11, were investigated for suppression of EAC colony and spheroid growth, induction of apoptosis and ROS generation in EAC cells.



Scheme 1. Reagents and conditions (yields in brackets): (i) 4-chlorobenzaldehyde, MeNH₂/EtOH, AcOH, 2 h, then TosMIC **2**, K₂CO₃, reflux, 6 h; (ii) MeI, MeCN, 85 °C, 24 h; (iii) a: Ag₂O, CH₂Cl₂, r.t., 24 h; b: AuCl(DMS), CH₂Cl₂, r.t., 18 h; (iv) KI, acetone, r.t., 24 h; (v) PPh₃, NaBF₄, acetone, r.t., 24 h; (vi) NaBF₄, acetone, r.t., 24 h; (vii) Ag₂O, CH₂Cl₂/MeOH, r.t., 5 h, then AuCl(DMS) (0.5 equiv.), r.t., 20 h; (viii) Ag₂O, CH₂Cl₂/MeOH, r.t., 24 h, then AuCl(DMS) (0.5 equiv.), LiBr, r.t., 6 h; (ix) Br₂, CH₂Cl₂, r.t., 3 h; (x) Ag₂O, CH₂Cl₂, r.t., 24 h; (xi) K₂PtCl₄, DMSO, 60 °C, 24 h.

2. Results

2.1. Chemistry

Based on the previously disclosed gold complex iodido-(1,3-diethyl-4-anisyl-5-(4-chlorophenyl)imidazol-2-ylidene)gold(I) **1a**, which exhibited high activity against esoph-

ageal adenocarcinoma (EAC) cells [24], further new gold(I)-, gold(III)-, and platinum(II)-NHC complexes bearing the 1,3-di(m)ethyl-4-anisyl-5-(4-chlorophenyl)imidazole-2-ylidene ligand system were prepared. Initially, the close 1,3-dimethylimidazol-2-ylidene analog iodido(1,3-dimethyl-4-anisyl-5-(4-chlorophenyl)imidazol-2-ylidene)gold(I) **6** was synthesized. Starting from the TosMIC compound **2** [26], the *N*-methylimidazole **3** was prepared. Methylation of **3** with iodomethane afforded the 1,3-dimethylimidazolium iodide **4**. The chlorido-gold(I) complex **5** was obtained from the reaction of **3** with Ag₂O, followed by treatment with AuCl(DMS). Reaction of the chlorido complex **5** with KI gave the analogous iodido complex **6**.

The known chlorido complex **7** [24] was used as a starting compound for the synthesis of the cationic PPh₃ complex **8**, which was obtained by reaction of **7** with PPh₃ and NaBF₄.

The imidazolium iodide salt **9** [24] was the starting compound for the synthesis of the cationic bis-NHC gold complex **11** via the corresponding BF₄[−] salt **10**. Imidazolium **9** was also applied for the synthesis of the bromidogold(I) complex **12** upon reaction with Ag₂O followed by treatment with AuCl(DMS) and LiBr [27]. The analogous trisbromido-gold(III) complex **13** was obtained from the reaction of **12** with Br₂ [28]. The iodido-silver(I) complex **14** was prepared from **9** and Ag₂O. The reaction of **14** with K₂PtCl₄ in DMSO furnished the *cis*-dichlorido(DMSO)platinum(II) complex **15**. However, we were not able to obtain a bis-PPh₃ Pt(II) complex with the 1,3-diethyl-4-anisyl-5-(4-chlorophenyl)imidazole-2-ylidene ligand system as a close analog of the known complex **1c** [25].

The new complexes were analyzed using nuclear magnetic resonance (¹H and ¹³C NMR for each complex and ¹¹B, ³¹P, and ¹⁹⁵Pt NMR for the respective complexes) and mass spectrometry (EI and ESI-HRMS, see Section 4.3, and Figures S1–S25 in the supplementary materials). Elemental analyses were performed for the halogenido complexes **5**, **6**, **12–15**, for which HRMS experiments were not performed due to expected stability issues such as halogenido ligand loss and exchange under ESI conditions in aqueous solvents (e.g., water/acetonitrile mixtures). In terms of stability and degradation studies of analogous halogenidogold(I)-NHC complexes, we refer to our previous work [24].

The disappearance of the imidazole-NCHN proton signal in the ¹H NMR spectra of the complexes is a clear indicator for the coordination of the imidazol-2-ylidene ligand to the corresponding gold(I), gold(III), or platinum(II) center, together with a characteristic chemical shift in the metal-bound imidazole-NCN carbon signal in the ¹³C NMR spectra of the NHC complexes. The coupling constants (*J*) of the imidazole-2-ylidene ligand phenyl proton doublet signals were between 8.5 and 8.9 Hz, as expected for *para*-substituted benzene rings [24].

2.2. Cytotoxic Activity and Colony Formation Assay

The antiproliferative activities of complexes **5**, **6**, **11–13**, and **15** against four EAC cell lines (FLO-1, SK-GT-4, OE19, and OE33) were evaluated using the hexosaminidase assay (Table 1). The known complexes **1a–c** and the approved drugs auranofin and cisplatin served as positive control complexes. The iodidogold(I) complex **6** was distinctly more active than its chloridogold(I) analog **5** against OE19 cells. In the other three EAC cell lines, complex **5** was slightly more active than **6**. Notably, the 1,3-dimethylimidazolylidene **6** was less active against SK-GT-4 and FLO-1 cells than the 1,3-diethylimidazolylidene **1a**. The bromidogold(I) complex **12** and the trisbromidogold(III) complex **13** were less active than the iodido analog **1a** against two EAC cell lines (SK-GT-4 and FLO-1). Complex **12** was twice as active as **13** against FLO-1 and OE19 cells, while they showed comparable activities against SK-GT-4 and OE33 cells.

Table 1. Inhibitory activities (IC₅₀ values)¹ of complexes **5**, **6**, **11–13**, and **15**. Complexes **1a–c**, cisplatin, and auranofin served as positive controls.

Compound	SK-GT-4	FLO-1	OE19	OE33
1a ²	0.26 ± 0.09	0.12 ± 0.01	-	-
1b	4.63 ± 0.15	8.03 ± 0.25	10.67 ± 1.53	10.60 ± 2.75
1c	0.21 ± 0.01	0.43 ± 0.13	0.55 ± 0.08	0.19 ± 0.01
5	8.97 ± 0.15	4.77 ± 0.61	18.07 ± 3.39	2.32 ± 0.10
6	12.3 ± 0.10	4.83 ± 0.57	1.82 ± 0.73	4.57 ± 0.15
8 (G2)	0.84 ± 0.46	1.41 ± 0.44	1.27 ± 0.19	0.51 ± 0.04
11 (G4)	0.21 ± 0.04	0.33 ± 0.18	0.61 ± 0.16	0.20 ± 0.02
12	14.6 ± 0.35	4.80 ± 0.26	5.06 ± 1.12	2.3 ± 0.99
13	12.7 ± 0.1	17.13 ± 1.63	14.17 ± 2.36	3.77 ± 0.15
15	15.9 ± 0.1	>40	6.95 ± 3.28	>20
Auranofin	1.87 ± 1.01	2.82 ± 1.07	1.17 ± 0.55	2.20 ± 0.20
Cisplatin	2.05 ± 0.26	1.02 ± 0.29	1.03 ± 0.55	1.37 ± 0.25

¹ IC₅₀ values are presented in µM concentrations at the 72 h time-point (±SD). ² Values are also presented in ref. [24].

The cationic NHC-gold(I) complexes **8** and **11** (also referred to as G2 and G4, respectively, in the following mechanistic studies) were the most active complexes in the new series. The bis-carbene complex **11** exhibited high (nanomolar) activity, comparable to that of the previously reported iodidogold(I) complex **1a**, and it was more active than auranofin and cisplatin [24]. The new *cis*-dichlorido-DMSO-Pt(II) complex **15** was more active than its *N,N*-bisbenzyl analog **1b** against OE19 cells but distinctly less active than **1b** against SK-GT-4 and FLO-1 cells. Actually, **15** was inactive against FLO-1 and OE33 cells. The known bis-PPh₃ complex **1c** was the most active Pt(II) complex in this study, surpassing the activity of cisplatin and the DMSO complexes and falling within the IC₅₀ range of the highly active gold complexes **1a** and **11**. It is worth noting that cisplatin was more active against FLO-1 than against SK-GT-4 cells, whereas the NHC-Pt complexes **1b**, **1c**, and **15** were more active against SK-GT-4 than against FLO-1 cells. Notably, complexes **8** (G2) and **11** (G4) did not affect the proliferation of the non-malignant esophageal cell line Het-1A at concentrations below 5 µM after 72 h. We observed cytotoxicity in these cells at higher doses of 5–10 µM, which are approximately 3.5–22-fold higher than their IC₅₀ values in EAC cells, suggesting a considerable selectivity of **8** and **11** for cancer cells while sparing normal cells (Figure S26 and Table S1). Similarly, in THP-1 monocyte cells, complexes **8** and **11** did not show cytotoxicity at concentrations up to 5 µM, whereas a slight cytotoxicity (below 50%) was observed at 10 µM after 72 h.

The dose- and time-dependent activity of the cationic NHC-gold(I) complexes **8** (G2) and **11** (G4) against SK-GT-4, OE33, and FLO-1 EAC cells was investigated and compared with the activity of auranofin (Figure 2). After 24 h, complexes **8** and **11** showed only weak activity even at higher concentrations, whereas both complexes exhibited higher activity already at low doses after 48 h and 72 h. In contrast, auranofin showed a quicker onset of activity at higher doses (already after 24 h) but remained less active than **8** and **11** at lower doses after longer incubation times (72 h). In comparison to the previously published data of **1a**, complexes **8** and **11** appeared to be more active than **1a**, which, in spite of its low IC₅₀ values, still showed ca. 20% (FLO-1) and ca. 40% (SK-GT-4) proliferating EAC cells at a concentration of 5 µM after 72 h [25]. We used the clonogenic assay to evaluate the long-term effects of complexes **8** (1.7 and 1.9 µM, respectively) and **11** (0.9 and 0.7 µM, respectively) in EAC cell lines OE33 and FLO-1 for 48 h. Both complexes significantly reduced colony number and size in OE33 and FLO-1 cells (Figure 3A,B), suggesting that the effects of complexes **8** and **11** are irreversible.




Figure 2. Gold complexes **8** (G2), **11** (G4), and auranofin (Aur) inhibited proliferation in the SK-GT-4, OE33, and FLO-1 EAC cell lines. Cells treated with 0–10 μM of each compound for up to 72 h showed a dose- and time-dependent reduction in proliferation, indicating antiproliferative effects.

2.3. Complexes **8** and **11** Inhibit Spheroid Formation in EAC Cells

Complexes **8** (1.7 and 1.9 μM , respectively) and **11** (0.9 and 0.7 μM , respectively) inhibited spheroid formation by SK-GT-4 and FLO-1 EAC cells (Figure 4). The inhibitory effects of both complexes were more pronounced on FLO-1 spheroids, with a nearly complete inhibition at the applied concentrations. The inhibition of spheroid formation by **8** and **11** was also more pronounced in comparison with previous results for complex **1a** in these EAC cell lines [24].

2.4. Complexes **8** and **11** Induce Apoptosis in EAC Cells

To investigate the cell death mechanisms induced by complexes **8** and **11**, their potential to induce apoptosis in SK-GT-4 and OE33 EAC cells was assessed using the AnnexinV/PI assay and flow cytometry. Notably, cells treated with **8** and **11** (IC_{50} concentrations) for 72 h showed a considerable induction of both early and late apoptotic cells but only marginal numbers of necrotic cells, compared with untreated control populations (Figure 5).

In contrast, complex **1a** had not induced early apoptosis in SK-GT-4 cells in our previously published study [24].




Figure 3. Gold complexes **8** (G2) and **11** (G4) inhibit EAC cell colony formation. (A) Cells treated with complexes **8** (G2) and **11** (G4) for 48 h, followed by 10–14 days of culture in compound-free media, revealed that both complexes significantly reduced colony formation, indicating suppressed clonogenic potential. (B) Quantification confirmed a significant decrease in colony numbers in treated cells compared with vehicle-treated cells.

As another indicator of apoptosis induction, the activation of caspases 3 and 7 by complexes **8** and **11** was studied (Figure 6). Both gold complexes **8** (1.7 and 1.9 μM , respectively) and **11** (0.9 and 0.7 μM , respectively) exhibited a 3–4-fold increase in caspase 3 and 7 activity in SK-GT-4 and FLO-1 EAC cells. The cells were then treated with auranofin, as previously reported, as it induces caspase 3/7 activity in a dose-dependent manner [29]. However, when the cells were treated with **8** (G2) or auranofin, an equivalent dose of the most potent compound, **11** (G4), did not result in significant caspase 3/7 activity in SK-GT-4 and FLO-1 cells, suggesting the superiority of complex **11** (G4) in inducing apoptosis.

To investigate the effects of complexes **8** (1.7 and 1.9 μM , respectively) and **11** (0.9 and 0.7 μM , respectively) on anti-apoptotic proteins Bcl-XL, Bcl-2, and Mcl-1 in SK-GT-4 and FLO1 cells, their expression was assessed and quantified by Western blot (Figures 7, S27 and S28). Both compounds **8** and **11** downregulated the expression of Bcl-

XL, Bcl-2, and Mcl-1 in EAC cells after 48 h. Moreover, the cell cycle protein cyclin D1 was strongly suppressed by **8** and **11**.




Figure 4. (A) Inhibition of EAC cell spheroid formation by gold complexes **8** (G2) and **11** (G4, IC₅₀ concentrations). (B) The gold complexes **8** and **11** reduced the size and number of SK-GT-4 and FLO-1 EAC spheroids.

Auranofin has been reported to inhibit cytosolic and mitochondrial TrxR, thereby increasing reactive oxygen species (ROS) levels, which are associated with DNA damage, mitochondrial permeability transition, and an increased percentage of annexin V-positive cells [30]. To investigate the effects of our new complexes, we performed a fluorometric ROS assay on OE33 EAC cells treated with auranofin, complex **8** (G2), and complex **11** (G4). The results demonstrated that treatment with all compounds significantly increased ROS levels in OE33 cells in a dose-dependent manner, indicating the induction of oxidative stress and triggering apoptosis (Figure 8A). Additionally, a TrxR activity assay revealed a significant decrease in activity when cells were treated with auranofin, **8** (G2), and **11** (G4) at their respective IC₅₀ concentrations after 48 h of incubation (Figure 8B). Conversely, we did not observe any ROS generation in Het-1A cells (Figure S29), suggesting the selectivity of these compounds towards EAC cells. Although further experiments are needed to establish a direct link between TrxR inhibition and ROS-driven apoptosis in EAC cells, we believe that this decrease in TrxR activity correlates with increased oxidative stress and apoptosis induction.




Figure 5. Gold complexes 8 (G2) and 11 (G4) induced early- and late-phase apoptosis in SK-GT-4 and OE33 cells, as assessed by Annexin-PI flow cytometry. The data were expressed as mean $\pm$ SD and analyzed by one-way ANOVA.




Figure 6. Gold complexes 8 (G2) and 11 (G4) induced apoptosis in SK-GT-4 and FLO-1 cells, as assessed by activation of caspases 3 and 7 activity. Auranofin (Aur) was applied as reference drug. The data were expressed as mean $\pm$ SD and analyzed by one-way ANOVA.




Figure 7. Gold complexes **8** (G2) and **11** (G4, IC₅₀ concentrations, 72 h) suppressed anti-apoptotic proteins Bcl-XL, Bcl-2, and MCL1, as well as the cell cycle factor cyclin D1.




Figure 8. Gold complexes **8** (G2), **11** (G4), and auranofin (Aur) induced (A) ROS production in the EAC cell line OE33 in a dose-dependent manner, and (B) decreased TrxR activity in OE33 and SK-GT-4 cell lines.

3. Discussion

New metal complex derivatives of the recently disclosed neutral 4-anisyl-5-(4-chlorophenyl)imidazol-2-ylidene-iodidogold(I) complex **1a** were prepared by changing the *N*-ethyl substituents, the iodido ligand, and/or the metal ion and its oxidation state. The synthesis of the new gold-NHC complexes **5**, **6**, **8**, **11–13** and platinum(II) complex **15** was straightforward using published procedures [15,16,24,25,27,28]. In this way, two antitumoral cationic gold(I)-NHC complexes, **8** and **11**, were discovered. Complex **11** in particular exhibited high activities in the range of those of the iodidogold(I) complex **1a**. Cationic NHC-gold(I) complexes were often found distinctly more active against cancer cells than their neutral chloridogold(I)-NHC analogs, while iodidogold(I) complexes reached excellently low IC₅₀ values in cancer cells, similar to those of known cationic triphenylphosphinogold(I)-NHC complexes and biscarbene-gold(I) complexes [2,31,32]. It is also noteworthy that marginal modifications of the *N*-alkyl substituent of the imidazole ring (*N*-methyl instead of *N*-ethyl) of the 4-anisyl-5-(4-chlorophenyl)imidazole-based NHC ligand system applied in this study led to a substantial decrease in anticancer activity. This finding is in line with our previous reports that *N*-ethyl imidazole ring substituents are superior to *N*-methyl substituents in neutral chloridogold(I) complexes [31]. The replacement of the iodido ligand of **1a** by a bromido ligand, as in complex **12**, also reduced the anticancer activity as reported previously by Bian and coworkers for diarylimidazolylidene gold(I) complexes [32]. In a similar vein, the trisbromidogold(III) complex **13** showed only moderate activities and lower activities than the analogous bromidogold(I) complex **12** in two cell lines, indicating also an important role of the gold(I) oxidation state in the manifestation of anticancer activity against specific EAC cells. The *cis*-dichlorido(DMSO)platinum(II) complex **15** was only moderately active against SK-GT-4 and OE19 cells. It was inactive against FLO-1 cells, which is in stark contrast to the activity of **1b** and cisplatin against FLO-1 cells. Only in the OE19 cells, complex **15** was superior to **1b**. Notably, the known bis-PPh₃-platinum complex **1c** exhibited high activity against all tested EAC cell lines, which complements its previously reported anticancer activities against various other solid tumors [25]. Further on, complexes **8** and **11** demonstrated specificity towards cancer cells without inducing cytotoxicity in normal cell lines. Even at concentrations five times higher than those required to exhibit antiproliferative effects on EAC cells, these complexes did not prove themselves cytotoxic in the normal esophageal cell line Het-1A nor in the monocyte cell line THP-1. This suggests that complexes **8** and **11** are selectively toxic to cancer cells while sparing non-malignant and immune cells, which commends them for evaluation of their anticancer potential in future clinical trials.

Apoptosis is strongly induced by the most promising complexes **8** and **11**. This is consistent with previous reports on the induction of apoptosis by auranofin and complex **1a** in tumor cells [1,24]. However, complex **1a** did not induce early apoptosis in SK-GT-4 cells in our previously published study [24]. The pro-apoptotic activities of **8** and **11** were associated with a suppression of various anti-apoptotic proteins. In particular, the observed gold complex-mediated downregulation of Mcl-1 has been reported previously in association with apoptosis induction in FLO-1 and SK-GT-4 cells treated with other drugs [33]. The induction of apoptotic cell death by **8** and **11** is supported by the suppression of cyclin D1 and the inhibition of cell-cycle progression, including mitosis, in treated cells. Cyclin D1 is relevant to the progression of FLO-1 cells, and its suppression is also relevant to the treatment of other cancers, thereby broadening the therapeutic potential of the new cationic NHC-gold(I) complexes **8** and **11** [34,35].

The suppression of the formation of new EAC cell colonies and spheroids by complexes **8** and **11** is another promising effect, likely due to a consequent inhibition of cancer stem-like cells (CSCs). The effect of **8** and **11** on EAC spheroids appears to be more pronounced

than that of **1a** [24]. The inhibition of tumor growth by CSCs and the reversal of the mesenchymal properties of EAC cells are crucial for blocking EAC metastasis [36]. In FLO-1 and SK-GT-4 EAC cells, EMT reversal can also reduce cancer cell motility and invasion [37].

Our study demonstrates that auranofin and gold complexes **8** and **11** significantly induce ROS generation in the EAC cell line OE33. Auranofin, known for its anti-rheumatic effects, inhibits TrxR, disrupts the cell's redox balance, and increases ROS formation, leading to oxidative stress and apoptosis of cancer cells. By extending this mechanism to EAC cells, auranofin effectively induced ROS and cytotoxicity. Gold complexes **8** and **11** similarly inhibited TrxR and increased ROS levels in EAC cells. This ROS-mediated cytotoxicity is specific to cancer cells, as these complexes showed minimal toxicity and no ROS generation in normal esophageal Het-1A and monocyte THP-1 cells, even at higher concentrations, underscoring their potential for targeted therapy. The probable mechanism behind the inhibition of TrxR activity may involve binding to crucial cysteine and selenocysteine residues by the newly described gold(I) complexes, but further research is needed to confirm this. The combination of gold complexes with HDAC inhibitors might be promising given the known effects of HDAC inhibition on thioredoxin and thioredoxin-interacting proteins in EAC [38,39].

Moreover, increased ROS formation can modulate the tumor immune response. An auranofin-type (triethylphosphine)gold complex with the clinically approved EGFR inhibitor erlotinib upregulated ROS formation in acute myeloid leukemia (AML) models, which was accompanied by a differentiation of AML cells to dendritic cells and a modulation of the immune microenvironment [40]. Analogously, NHC-gold(I) complex conjugates with glabridin and triterpene molecules enhanced ROS formation and induced dendritic cell maturation and immunogenic cell death in liver cancers [41,42]. Notably, a dinuclear NHC-gold(I) complex based on a dimeric bis-4,5-di(4-fluorophenyl)imidazol-2-ylidene ligand system also exhibited promising in vitro and in vivo activities against liver cancer models based on upregulated ROS levels leading to endoplasmic reticulum stress and ferroptosis associated with enhanced immunogenic cell death [43]. Thus, a beneficial immunomodulatory mechanism of the gold(I) complexes **8** and **11** in the tumor microenvironment can be expected based on their proven ROS-forming properties in EAC cells, albeit these immune effects remain to be evaluated in future studies.

Our findings indicate that the gold complexes **8** and **11** are promising anticancer agents, as they induce ROS formation and apoptosis in EAC cells. The current manuscript did not establish the mechanistic link between **8**- and **11**-induced inhibition of TrxR activity, increased oxidative stress, and apoptosis induction in EAC cells. This is a limitation of the study, and further research is needed to clarify the exact molecular pathways, conduct drug-protein target binding assays, evaluate in vivo activity, and investigate suitable combination therapies to improve treatment effectiveness.

4. Materials and Methods

4.1. General Procedures

Column chromatography: silica gel 60 (230–400 mesh, Merck, Darmstadt, Germany). Melting points (uncorrected), Electrothermal 9100 (Thermo Fisher Scientific, Geel, Belgium); IR spectra, Perkin-Elmer Spectrum One FT-IR spectrophotometer with an ATR sampling unit (Perkin Elmer, Rodgau, Germany); NMR spectra, Bruker Avance 300/500 spectrometer (Bruker, Billerica, MA, USA); chemical shifts (δ) are given in parts per million (ppm) downfield from tetramethylsilane as an internal standard; mass spectra, Thermo Finnigan MAT 8500 (EI), UPLC/Orbitrap (ESI-HRMS, using water/acetonitrile mixtures as solvent, Thermo Fisher Scientific, Geel, Belgium).

4.2. Materials

Starting compounds and reagents were obtained from abcr (Karlsruhe, Germany), Sigma-Aldrich (Darmstadt, Germany), and TCI (Zwijndrecht, Belgium). The complexes **1a–c** and **7**, as well as the imidazolium salt **9** used in this study, were prepared and published before [24,25]. The anisyl-TosMIC compound **2** was synthesized according to a reported procedure [26].

4.3. Synthesis

1-Methyl-4-anisyl-5-(4-chlorophenyl)imidazole (3)

4-Chlorobenzaldehyde (59 mg, 0.42 mmol) was dissolved in ethanol (15 mL), treated with 33% MeNH₂/EtOH (260 mL, 2.10 mmol) and acetic acid (150 mL, 2.63 mmol), and heated for 2 h under reflux. Anisyl-TosMIC **2** (127 mg, 0.44 mmol) and K₂CO₃ (500 mg, 3.62 mmol) were added and the reaction mixture was stirred for 4 h under reflux. The volatiles were evaporated and the residue was suspended in ethyl acetate, washed with water, dried over Na₂SO₄, filtered, and the filtrate was concentrated in vacuum. The residue was purified by column chromatography (ethyl acetate, silica gel 60). Yield: 83 mg (0.28 mmol, 67%); colorless amorphous solid; $\nu_{\max}$ (ATR)/cm^{−1} 2989, 2938, 2836, 1613, 1578, 1514, 1496, 1483, 1453, 1416, 1371, 1294, 1247, 1194, 1171, 1120, 1091, 1029, 1013, 955, 833, 808, 798, 744, 735, 704, 654; ¹H NMR (300 MHz, CDCl₃) δ 3.45 (3 H, s), 3.74 (3 H, s), 6.7–6.8 (2 H, m), 7.2–7.3 (2 H, m), 7.3–7.5 (4 H, m), 7.52 (1 H, s); ¹³C NMR (75.5 MHz, CDCl₃) δ 32.2, 55.2, 113.6, 113.8, 114.4, 126.5, 128.1, 127.6, 127.9, 129.2, 131.9, 134.5, 137.6, 137.0, 137.6, 138.6, 158.4; *m/z* (EI, %) 298 (100) [M⁺], 283 (33), 220 (17), 152 (13).

1,3-Dimethyl-4-anisyl-5-(4-chlorophenyl)imidazolium iodide (4)

1-Methyl-4-anisyl-5-(4-chlorophenyl)imidazole **3** (78 mg, 0.26 mmol) was dissolved in acetonitrile (25 mL) and iodomethane (2 mL) was added. The reaction mixture was stirred at 85 °C for 24 h. The solvent was evaporated and the residue was dried in vacuum. Yield: 110 mg (0.25 mmol, 96%); yellow gum; $\nu_{\max}$ (ATR)/cm^{−1} 3429, 3007, 2964, 2837, 1628, 1607, 1577, 1517, 1495, 1418, 1398, 1294, 1251, 1178, 1111, 1090, 1051, 1013, 919, 861, 837, 817, 792, 725, 668; ¹H NMR (300 MHz, CDCl₃) δ 3.75 (3 H, s), 3.83 (3 H, s), 3.86 (3 H, s), 6.8–6.9 (2 H, m), 7.1–7.3 (2 H, m), 7.2–7.4 (4 H, m), 10.15 (1 H, s); ¹³C NMR (75.5 MHz, CDCl₃) δ 34.9, 35.2, 55.3, 114.6, 116.1, 116.5, 123.3, 129.4, 130.8, 131.9, 132.0, 132.5, 136.5, 136.8, 160.9; *m/z* (EI, %) 298 (100) [M⁺-CH₃], 283 (13), 220 (12), 142 (61), 127 (23).

Chlorido-[1,3-dimethyl-4-anisyl-5-(4-chlorophenyl)imidazole-2-ylidene]gold(I) (5)

A mixture of imidazolium salt **4** (116 mg, 0.26 mmol), CH₂Cl₂ (15 mL), and silver(I) oxide (60 mg, 0.26 mmol) was stirred at room temperature in the dark for 1 d. The suspension was filtered through Celite and the filtrate was concentrated in vacuum. The residue was dissolved in CH₂Cl₂ and the silver(I) compound iodido-[1,3-dimethyl-4-anisyl-5-(4-chlorophenyl)imidazole-2-ylidene]silver(I) (82 mg, 0.15 mmol, 58%) was precipitated with *n*-hexane. The silver(I) intermediate was dissolved in CH₂Cl₂ (15 mL) and treated with chloro(dimethylsulfide)gold(I) (55 mg, 0.18 mmol). The reaction mixture was stirred at room temperature for 18 h. The suspension was filtered, the filtrate was concentrated in vacuum, and the residue recrystallized from CH₂Cl₂/*n*-hexane. Yield: 66 mg (0.12 mmol, 81%); amber solid of m.p. 210–211 °C; ¹H NMR (300 MHz, CDCl₃) δ 3.70 (3 H, s), 3.72 (3 H, s), 3.80 (3 H, s), 6.8–6.9 (2 H, m), 7.0–7.2 (4 H, m), 7.33 (2 H, d, *J* = 8.6 Hz); ¹³C NMR (75.5 MHz, CDCl₃) δ 36.7, 36.8, 55.3, 114.6, 114.5, 119.1, 19.7, 126.2, 129.3, 130.2, 131.6, 131.7, 131.9, 135.6, 160.4, 171.2; *m/z* (EI, %) 544 (96) [M⁺], 509 (100), 347 (17), 298 (16), 255 (17), 50 (64). Anal. Calcd. For C₁₈H₁₇AuCl₂N₂O: C, 39.65%; H, 3.14%; Found: C, 39.79%; H, 3.22%.

Iodido-[1,3-dimethyl-4-anisyl-5-(4-chlorophenyl)imidazole-2-ylidene]gold(I) (6)

Chlorido-[1,3-dimethyl-4-anisyl-5-(4-chlorophenyl)imidazole-2-ylidene]gold(I) **5** (60 mg, 0.11 mmol) and KI (73 mg, 0.439 mmol) were dissolved in acetone (2 mL) and the reaction mixture was stirred at room temperature for 24 h. The solvent was evaporated, the residue was dissolved in CH₂Cl₂ and filtered over celite followed by filtration over a plug of silicate. The residue was recrystallized from CH₂Cl₂/*n*-hexane. Yield: 56 mg (0.088 mmol, 80%); off-white solid of mp 190–191 °C; ¹H NMR (300 MHz, CDCl₃) δ 3.70 (3 H, s), 3.73 (3 H, s), 3.79 (3 H, s), 6.8–6.9 (2 H, m), 7.1–7.3 (4 H, m), 7.34 (2 H, d, *J* = 8.7 Hz); ¹³C NMR (75.5 MHz, CDCl₃) δ 36.3, 36.4, 55.3, 114.3, 114.5, 119.1, 119.7, 126.1, 129.3, 130.1, 131.6, 131.7, 135.6, 160.4, 181.5; *m/z* (EI, %) 636 (51) [M⁺], 509 (100), 465 (8), 255 (10), 215 (7). Anal. Calcd. For C₁₈H₁₇ClIN₂O: C, 33.96%; H, 2.69%; Found: C, 34.06%; H, 2.72%.

Chlorido-[1,3-diethyl-4-anisyl-5-(4-chlorophenyl)imidazole-2-ylidene]gold(I) (7) [24]

Iodido-[1,3-diethyl-4-anisyl-5-(4-chlorophenyl)imidazole-2-ylidene]silver(I) (77 mg, 0.134 mmol) was dissolved in CH₂Cl₂ (15 mL) and treated with chloro(dimethylsulfide)gold(I) (49 mg, 0.16 mmol). The reaction mixture was stirred at room temperature for 18 h. The suspension was filtered, the filtrate was concentrated in vacuum, and the residue recrystallized from CH₂Cl₂/*n*-hexane. Yield: 62 mg (0.11 mmol, 82%) [24].

Triphenylphosphino-[1,3-diethyl-4-anisyl-5-(4-chlorophenyl)imidazole-2-ylidene]gold(I) tetrafluoroborate (8)

Chlorido-[1,3-diethyl-4-anisyl-5-(4-chlorophenyl)imidazole-2-ylidene]gold(I) **7** (62 mg, 0.11 mmol) was dissolved in acetone (10 mL) and treated with NaBF₄ (23 mg, 0.205 mmol) and PPh₃ (38 mg, 0.143 mmol). The reaction mixture was stirred at room temperature for 24 h. The suspension was filtered, the filtrate was concentrated in vacuum, and the residue recrystallized from CH₂Cl₂/*n*-hexane. Yield: 90 mg (0.10 mmol, 91%); colorless solid of m.p. 110 °C (dec.); ¹H NMR (300 MHz, CDCl₃/acetone-*d*₆) δ 1.3–1.5 (6 H, m), 3.81 (3 H, s), 4.3–4.4 (4 H, m), 6.99 (2 H, d, *J* = 8.9 Hz), 7.36 (2 H, d, *J* = 8.8 Hz), 7.4–7.7 (19 H, m); ¹³C NMR (75.5 MHz, acetone-*d*₆) δ 17.1, 17.2, 45.0, 45.2, 55.8, 115.1, 115.2, 120.2, 120.7, 127.7, 129.9, 130.0, 131.5, 132.7, 133.1, 133.2, 133.5, 133.6, 135.7, 136.1, 161.5, 161.7, 183.4; ³¹P NMR (121.5 MHz, acetone-*d*₆) δ 40.8; ¹¹B NMR (96.3 MHz, acetone-*d*₆) δ −0.89; HR-MS (ESI) for C₃₈H₃₆ON₂AuClP [M⁺-BF₄], calcd. 799.1914, found 799.1923.

1,3-Diethyl-4-anisyl-5-(4-chlorophenyl)imidazolium tetrafluoroborate (10)

A mixture of 1,3-diethyl-4-anisyl-5-(4-chlorophenyl)imidazolium iodide **9** (119 mg, 0.348 mmol), acetone (30 mL), and NaBF₄ (59 mg, 0.54 mmol) was stirred at room temperature for 24 h. The mixture was filtered over MgSO₄, the filtrate was concentrated in vacuum, and the residue was dried. Yield: 128 mg (0.348 mmol, 100%); yellow gum; *v*_{max}(ATR)/cm^{−1} 3425, 3129, 2980, 2938, 2837, 1607, 1559, 1517, 1493, 1460, 1398, 1352, 1294, 1251, 1177, 1068, 1015, 839, 806, 783, 733, 709, 655; ¹H NMR (300 MHz, acetone-*d*₆) δ 1.4–1.5 (6 H, m), 3.81 (3 H, s), 4.2–4.3 (4 H, m), 6.9–7.0 (2 H, m), 7.4–7.5 (4 H, m), 7.6–7.7 (2 H, m), 9.80 (1 H, s); ¹³C NMR (75.5 MHz, acetone-*d*₆) δ 15.4, 15.5, 43.7, 44.0, 55.8, 115.2, 118.2, 125.8, 133.1, 133.3, 133.4, 133.8, 135.9, 136.5, 161.9; ¹¹B NMR (96.3 MHz, acetone-*d*₆) δ −0.46. *m/z* (ESI, %) 341.1405 (100) [M⁺-BF₄], 337.1907 (40).

Bis-[1,3-diethyl-4-anisyl-5-(4-chlorophenyl)imidazole-2-ylidene]gold(I) tetrafluoroborate (11)

Imidazolium salt **10** (120 mg, 0.32 mmol) was dissolved in CH₂Cl₂/methanol (1:1, 30 mL) and treated with Ag₂O (84 mg, 0.34 mmol). The resulting mixture was stirred in the dark at room temperature for 5 h. Chloro(dimethylsulfide)gold(I) (56 mg, 0.184 mmol) was added and stirring was continued for a further 20 h. The suspension was filtered,

the filtrate was concentrated in vacuum, and the residue was redissolved in CH_2Cl_2 , and filtered over $\text{MgSO}_4/\text{Celite}$. The filtrate was concentrated and the remainder was dried in vacuum. Yield: 113 mg (0.12 mmol, 65%); colorless solid of m.p. 136–137 °C (dec.); ^1H NMR (300 MHz, $\text{CDCl}_3/\text{acetone-d}_6$) δ 1.2–1.3 (6 H, m), 1.4–1.5 (3 H, m), 3.80 (3 H, s), 3.82 (3 H, s), 4.1–4.2 (4 H, m), 4.3–4.4 (4 H, m), 6.9–7.0 (4 H, m), 7.2–7.4 (8 H, m), 7.4–7.5 (4 H, m); ^{13}C NMR (75.5 MHz, acetone-d_6) δ 17.8, 17.9, 45.2, 45.4, 55.8, 115.2, 115.3, 119.8, 120.4, 127.5, 129.5, 130.0, 130.3, 130.6, 130.7, 131.8, 132.7, 132.8, 132.9, 133.2, 133.5, 133.6, 134.1, 135.0, 135.2, 136.0, 161.7, 185.4; ^{31}P NMR (121.5 MHz, acetone-d_6) δ 40.8; ^{11}B NMR (96.3 MHz, acetone-d_6) δ −0.96; HR-MS (ESI) for $\text{C}_{40}\text{H}_{42}\text{O}_2\text{N}_4\text{AuCl}_2$ [$\text{M}^+ - \text{BF}_4$], calcd. 877.2345, found 877.2356.

Bromido[1,3-diethyl-4-anisyl-5-(4-chlorophenyl)imidazole-2-ylidene]gold(I) (12)

Imidazolium salt **9** (103 mg, 0.22 mmol) in a mixture of CH_2Cl_2 (6 mL) and methanol (2 mL) was combined with silver(I) oxide (29 mg, 0.12 mmol) and stirred overnight under protection from light. Then Me_2SauCl (65 mg, 0.22 mmol) and LiBr (191 mg 2.2 mmol) were added and the suspension was stirred for an additional 6 h. The gray precipitate was separated by filtration over a bed of Celite and silica gel, and the filtrate was evaporated to dryness under reduced pressure to yield a colorless oil. The residue was recrystallized from $\text{CH}_2\text{Cl}_2/n$ -hexane. Yield: 130 mg (0.21 mmol, 96%); off-white solid of m.p. 182–183 °C (dec.); ^1H NMR (300 MHz, CDCl_3) δ 1.2–1.3 (6 H, m), 3.79 (3 H, s), 4.1–4.2 (4 H, m), 6.8–6.9 (2 H, m), 7.0–7.2 (4 H, m), 7.32 (2 H, d, J = 8.7 Hz); ^{13}C NMR (75.5 MHz, CDCl_3) δ 16.9, 44.2, 44.3, 55.3, 114.3, 114.5, 119.3, 119.9, 126.4, 129.3, 130.7, 131.3, 131.7, 131.8, 135.6, 160.4, 173.0; m/z (EI, %) 618 (32) [M^+], 537 (100), 465 (8), 255 (10), 215 (7). Anal. Calcd. For $\text{C}_{20}\text{H}_{21}\text{AuBrClN}_2\text{O}$: C, 38.89%; H, 3.43%; Found: C, 38.95%; H, 3.48%.

Trisbromido[1,3-diethyl-4-anisyl-5-(4-chlorophenyl)imidazole-2-ylidene]gold(III) (13)

To a solution of bromido[1,3-diethyl-4-anisyl-5-(4-chlorophenyl)imidazole-2-ylidene]gold(I) **12** (72 mg, 0.12 mmol) in CH_2Cl_2 (2 mL) was added bromine (28 mg, 0.18 mmol). The mixture was stirred for 3 h in the dark, and the solvent was removed under reduced pressure, as well as the excess of bromine. The residue was recrystallized from $\text{CH}_2\text{Cl}_2/n$ -hexane. Yield: 81 mg (0.10 mmol, 87%); orange solid of m.p. 105 °C (dec.); ^1H NMR (300 MHz, CDCl_3) δ 1.3–1.4 (6 H, m), 3.80 (3 H, s), 4.2–4.3 (4 H, m), 6.8–7.0 (2 H, m), 7.1–7.2 (4 H, m), 7.37 (2 H, d, J = 8.5 Hz); ^{13}C NMR (75.5 MHz, CDCl_3) δ 15.3, 44.2, 44.3, 55.4, 114.5, 114.7, 117.6, 118.2, 124.8, 129.5, 131.8, 131.9, 132.0, 132.7, 133.8, 134.3, 136.5, 138.6, 160.9; m/z (EI, %) 618 (33) [$\text{M}^+ - 2\text{Br}$], 537 (100), 269 (15), 160 (20), 96 (36). Anal. Calcd. For $\text{C}_{20}\text{H}_{21}\text{AuBr}_3\text{ClN}_2\text{O}$: C, 30.90%; H, 2.72%; Found: C, 30.96%; H, 2.78%.

Iodido-[1,3-diethyl-4-anisyl-5-(4-chlorophenyl)imidazole-2-ylidene]silver(I) (14)

A mixture of imidazolium salt **9** (105 mg, 0.22 mmol), CH_2Cl_2 (15 mL), and silver(I) oxide (51 mg, 0.22 mmol) was stirred at room temperature in the dark for 1 d. The suspension was filtered through Celite and the filtrate was concentrated in vacuum. The residue was dissolved in CH_2Cl_2 and the product precipitated with n -hexane. Yield: 93 mg (0.16 mmol, 73%); brown gum; ^1H NMR (300 MHz, CDCl_3) δ 1.2–1.3 (6 H, m), 3.79 (3 H, s), 4.0–4.2 (4 H, m), 6.8–6.9 (2 H, m), 7.0–7.2 (4 H, m), 7.31 (2 H, d, J = 8.5 Hz); ^{13}C NMR (75.5 MHz, CDCl_3) δ 17.4, 44.8, 44.9, 55.2, 114.2, 114.4, 119.6, 120.2, 126.7, 129.2, 130.2, 131.6, 131.7, 131.8, 135.4, 160.2, 183.2; m/z (EI, %) 576 (3) [M^+], 449 (48), 339 (100), 312 (49).

cis-Dichlorido-[1,3-diethyl-4-anisyl-5-(4-chlorophenyl)imidazole-2-ylidene]-dimethyl-sulfoxidoplatinum(II) (15)

The silver complex **14** (72 mg, 0.125 mmol) was dissolved in DMSO (6 mL), treated with K_2PtCl_4 (52 mg, 0.125 mmol), and stirred at 60 °C for 24 h. CH_2Cl_2 was added, the reaction mixture was filtered, and the filtrate was washed with water and dried over

Na₂SO₄. The volatiles were removed in vacuum and the remainder was recrystallized from CH₂Cl₂/*n*-hexane. Yield: 58 mg (0.085 mmol, 68%); amorphous solid; ¹H NMR (300 MHz, CDCl₃) δ 1.2–1.3 (6 H, m), 3.55 (6 H, s), 3.78 (3 H, s), 4.3–4.6 (4 H, m), 6.8–6.9 (2 H, m), 7.1–7.2 (4 H, m), 7.29 (2 H, d, *J* = 8.7 Hz); ¹³C NMR (75.5 MHz, CDCl₃) δ 15.6, 41.0, 43.9, 44.0, 46.2, 55.2, 114.1, 114.3, 119.3, 119.9, 126.4, 129.1, 130.1, 131.4, 131.8, 131.9, 135.4, 142.1, 160.3; ¹⁹⁵Pt NMR (64.3 MHz, CDCl₃) δ 959.8; *m/z* (EI, %) 535 (12) [M⁺-2Cl—DMSO], 506 (5), 340 (22), 313 (44), 120 (19), 44 (28), 36 (100). Anal. Calcd. For C₂₂H₂₇Cl₃N₂O₂PtS: C, 38.58%; H, 3.97%; Found: C, 38.66%; H, 4.00%.

4.4. Anticancer Activity

4.4.1. Cell Line and Culture Conditions

OE19, OE33 (Sigma-Aldrich), Het-1A (ATCC), FLO-1, THP-1, and SK-GT-4 cells (a gift from Dr. Anant's lab, University of Kansas Medical Center, KS) were cultured in complete RPMI (L-glutamine and HEPES, Corning, Lowell, MA, USA, and Cytiva, Marlborough, MA, USA). Complete RPMI was prepared by adding 10% fetal bovine serum (heat-inactivated, Biowest Bradenton, FL, USA) and 1% antibiotic-antimycotic solution (Corning, MA). Het-1A cells were cultured in complete BEBM media prepared as per instructions provided by the BEGM kit (Lonza/Clonetics Corporation, Walkersville, MD, USA, Catalog No. CC-3170). The cells were seeded in a coated flask with a mixture of 0.01 mg/mL fibronectin, 0.03 mg/mL bovine collagen type I, and 0.01 mg/mL bovine serum albumin dissolved in culture medium. EAC cells were cultured in a 5% CO₂ atmosphere at 37 °C. The stock solutions of the gold complexes were prepared in DMSO and diluted in the media to achieve the required concentration. The maximum DMSO concentration was 0.2%. All procedures were performed in accordance with standard guidelines and regulations, as well as with the manufacturer's instructions.

4.4.2. Proliferation Assay

5000 cells per well (SK-GT-4, FLO-1, OE19, Het-1A, and OE33) were seeded in a 96-well plate with complete media. After 24 h, cells were exposed to various concentrations of gold complexes. After 24–72 h, the medium was discarded, and cell viability was assessed using the hexosaminidase enzymatic assay [44]. A CCK-8 assay (Abcam#ab228554, Cambridge, MA, USA) was performed on THP-1 cells. Briefly, 5000 cells were seeded in each well of a 96-well plate. After 24 h, the cells were treated with the compounds. At the designated time points, an equal volume of CCK-8 reagent was added to the wells, and the plates were incubated for 1 h. Absorbance was then measured at 450 nm [45]. The percentage of inhibition was calculated by comparing cell viability after compound treatment with the viability of control cells.

4.4.3. Colony Formation Assay

500 EAC cells (FLO1 and OE33) per well were seeded in 6-well plates. After 24 h, the cells were treated with complexes **8** (1.7 and 1.9 μM, respectively) and **11** (0.9 and 0.7 μM, respectively). The media containing the compounds was replaced with complete RPMI after 48 h to eliminate the test substances. The cells were then cultured for 10–12 days to develop colonies. These colonies were washed with PBS, fixed with 10% formalin for 20 min, then washed again and stained with 1% crystal violet solution in 10% ethanol. Following staining, the colonies were rinsed to remove excess dye, dried, counted, and compared to control groups [46].

4.4.4. Spheroid Formation Assay

500 EAC cells were seeded in an ultra-low attachment 96-well plate (Corning, Lowell, MA, USA) using spheroid medium made from serum-free DMEM supplemented with

heparin salt (4 µg/mL), EGF (20 ng/mL), FGF (20 ng/mL), 1% antibiotic-antimycotic, and B27 supplement. After 2 days, spheroids were treated with **8** (1.7 and 1.9 µM, respectively) and **11** (0.9 and 0.7 µM, respectively). After 7 days, spheroids were counted and imaged [46].

4.4.5. Apoptosis Assay

200,000 EAC cells per well were seeded in a six-well plate with complete RPMI medium. After 24 h, the cells were treated with IC₅₀ concentrations of compounds **8** (1.4 and 1.7 µM, respectively) and **11** (0.23 and 0.14 µM, respectively). After 72 h of incubation, the cells were trypsinized, washed, and stained with the Annexin V-FITC Early Apoptosis Detection Kit (Cell Signaling Technology #6592, Danvers, MA, USA) according to the manufacturer's instructions, and finally analyzed by flow cytometry.

4.4.6. Caspase 3/7 Activation Assay

10,000 EAC cells (SK-GT-4 and FLO-1) per well were plated in an opaque, black, clear-bottom plate using complete RPMI media. After 24 h, the SK-GT-4 and FLO-1 cells were treated with complexes **8** (1.7 and 1.9 µM, respectively) and **11** (0.9 and 0.7 µM, respectively), and with an equivalent dose of complex **11** for auranofin and **8**. Following 48 h of incubation, the cells with media were exposed to Caspase 3/7 reagent (Caspase-Glo® 3/7 Assay System, Promega, G8090, Madison, WI, USA) at a 1:1 ratio to the media. After an additional hour of incubation, luminescent readings were taken using a plate reader [46].

4.4.7. Western Blot Analysis

500,000 EAC cells (SK-GT-4 and FLO-1) were seeded in a 10 cm Petri dish. After 24 h, they were treated with complexes **8** (1.7 and 1.9 µM, respectively) and **11** (0.9 and 0.7 µM, respectively) for 48 h. Cells were then washed, lysed in buffer containing phosphatase and protease inhibitors (Roche, Basel, Switzerland), and sonicated. The lysate was centrifuged at 6000 rpm for 10 min at 4 °C. Protein content was measured using the Pierce BCA assay. Equal amounts (50 µg) of protein from each sample were run on gel electrophoresis and transferred onto PVDF membranes (Millipore, Burlington, MA, USA) at 90 V for 2 h under cold conditions. The membranes were blocked with 5% non-fat skimmed milk in TBST for 1 h, washed, and then incubated with primary antibodies at 4 °C overnight. The next day, membranes were washed and incubated with secondary anti-mouse and anti-rabbit antibodies (Cell Signaling Technology, Danvers, MA, USA) for 1 h. Proteins were detected using the GE Healthcare chemiluminescence system and imaged with the Bio-Rad ChemiDoc-XRS+ system, with images processed in Image Lab. Antibodies for cyclin D1 (CST#2922), Bcl-XL (CST#2762), Bcl-2 (CST#4223), and Mcl-1 (CST#4572) were obtained from Cell Signaling Technology (Danvers, MA, USA), while GAPDH (G-9) was purchased from Santa Cruz Biotechnology (Dallas, TX, USA).

4.4.8. Reactive Oxygen Species Assay

The ROS assay was performed with 10,000 OE33 cells per well, grown in complete RPMI medium in black, clear-bottom 96-well plates, and treated with auranofin, complex **8**, and complex **11** after 24 h. After 72 h, the wells were treated with the ROS staining kit from Abcam (Cellular ROS Assay Kit (Red), ab186027, Cambridge, MA, USA). After 37 min, readings were taken with a fluorometric plate reader (Ex/Em 520/605 nm) [47].

4.4.9. Thioredoxin Reductase Activity Assay

The TrxR activity assay was conducted in SK-GT-4 and OE33 cells using the Thioredoxin Reductase Colorimetric Assay Kit (Cayman Chemical, Item No. 10007892, Ann Arbor, MI, USA). Cells were seeded at a density of 600,000 cells per 10 cm tissue culture dish and incubated for 24 h. Following this incubation period, the cells were treated with

Auranofin, complex **8** (G2), and complex **11** (G4). After 48 h of treatment, the cells were collected and lysed. Then, the TrxR activity was measured colorimetrically. The lysates were incubated with DTNB and NADPH substrates, and absorbance was measured at one-minute intervals after a 30 s shaking incubation. A colorimeter set to 405 nm was used to measure absorbance, enabling determination of TrxR activity.

4.4.10. Statistical Analysis

All values are shown as the mean $\pm$ SD. Experimental data were examined using an unpaired two-tailed *t*-test or one-way ANOVA by comparing with the corresponding control group. A probability value of less than 0.05 was considered statistically significant.

Supplementary Materials: The following supporting information can be downloaded at: <https://www.mdpi.com/article/10.3390/ijms27042032/s1>.

Author Contributions: Conceptualization, B.B. and P.D.; methodology, R.S., B.B. and P.D.; validation, formal analysis, H.G., T.R. and B.B.; investigation, H.G., T.R., S.B., D.V., M.L. and B.B.; resources, R.S. and P.D.; data curation, H.G., B.B. and P.D.; writing—original draft preparation, B.B. and P.D.; writing—review and editing, H.G. and R.S.; supervision, R.S., B.B. and P.D.; project administration, B.B. and P.D.; funding acquisition, R.S. and P.D. All authors have read and agreed to the published version of the manuscript.

Funding: R.S. thanks the Deutsche Forschungsgemeinschaft for financial support (grant Scho 402/12-2). P.D. thanks the University of Kansas Cancer Center and the Cancer Biology Department for providing start-up funding (Dandawate). Flow Cytometry Core Laboratory is partially sponsored by the NIH COBRE program of the NCRR P20 RR016443 and the University of Kansas Cancer Center P30CA168524–01 grants. The integrative imaging core was supported by the KIDDR (NIH U54 HD 090216) at the University of Kansas Medical Center, Kansas City, KS 66160. M.L. and P.D. thank Lida L. Moffett Foundation and KUMC's Accelerate Cancer Education (ACE) for funding support.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Original data can be requested from the corresponding author.

Acknowledgments: P.D. thanks the University of Kansas Cancer Center and the Cancer Biology Department for providing facilities. M.L. is a part of the Accelerate Cancer Education (ACE) program of KUMC.

Conflicts of Interest: The authors declare no conflicts of interest.

References

1. Onodera, T.; Momose, I.; Kawada, M. Potential anticancer activity of auranofin. *Chem. Pharm. Bull.* **2019**, *67*, 186–191. [[CrossRef](#)]
2. Thangamani, S.; Maland, M.; Mohammad, H.; Pascuzzi, P.E.; Avramova, L.; Koehler, C.M.; Hazbun, T.R.; Seleem, M.N. Repurposing approach identifies auranofin with broad spectrum antifungal activity that targets Mia40-Erv1 pathway. *Front. Cell. Infect. Microbiol.* **2017**, *7*, 4. [[CrossRef](#)] [[PubMed](#)]
3. Dickson-Murray, E.; Nedara, K.; Modjtahedi, N.; Tokatlidis, K. The Mia40/CHCHD4 oxidative folding system: Redox regulation and signaling in the mitochondrial intermembrane space. *Antioxidants* **2021**, *10*, 592. [[CrossRef](#)] [[PubMed](#)]
4. Liu, N.; Li, X.; Huang, H.; Zhao, C.; Liao, S.; Yang, C.; Liu, S.; Song, W.; Lu, X.; Lan, X.; et al. Clinically used antirheumatic agent auranofin is a proteasomal deubiquitinase inhibitor and inhibits tumor growth. *Oncotarget* **2014**, *5*, 5453–5471. [[CrossRef](#)] [[PubMed](#)]
5. Huang, H.; Liao, Y.; Liu, N.; Hua, X.; Cai, J.; Yang, C.; Long, H.; Zhao, C.; Chen, X.; Lan, X.; et al. Two clinical drugs deubiquitinase inhibitor auranofin and aldehyde dehydrogenase inhibitor disulfiram trigger synergistic anti-tumor effects in vitro and in vivo. *Oncotarget* **2016**, *7*, 2796–2808. [[CrossRef](#)]
6. Giorgini, D.; Chiaverini, L.; Viviano, M.; Belvedere, R.; Salerno, S.; Baglini, E.; da Settimo, F.; Marzo, T.; Taliani, S.; Barresi, E. Repurposing auranofin for oncology and beyond: A brief overview of clinical trials as mono- and combination therapy. *Pharmaceuticals* **2025**, *18*, 1628. [[CrossRef](#)]

7. Landini, I.; Massai, L.; Cirri, D.; Gamberi, T.; Paoli, P.; Messori, L.; Mini, E.; Nobili, S. Structure-activity relationships in a series of auranofin analogues showing remarkable antiproliferative properties. *J. Inorg. Biochem.* **2020**, *208*, 111079. [\[CrossRef\]](#)
8. Massai, L.; Cirri, D.; Marzo, T.; Messori, L. Auranofin and its analogs as prospective agents for the treatment of colorectal cancer. *Cancer Drug Resist.* **2022**, *5*, 1–14. [\[CrossRef\]](#)
9. Gamberi, T.; Chiappetta, G.; Fiaschi, T.; Modesti, A.; Sorbi, F.; Magherini, F. Upgrade of an old drug: Auranofin in innovative cancer therapies to overcome drug resistance and to increase drug effectiveness. *Med. Res. Rev.* **2022**, *42*, 1111–1146. [\[CrossRef\]](#)
10. Checoni, P.; Mariconda, A.; Catalano, A.; Ceramella, J.; Pellegrino, M.; Aquaro, S.; Sinicropi, M.S.; Longo, P. Searching for new gold(I)-based complexes as anticancer and/or antiviral agents. *Molecules* **2025**, *30*, 1726. [\[CrossRef\]](#)
11. Hoffmann, M.E.; Kühn, F.E. Au NHC complexes as anticancer agents: Milestones, strategies and future developments. *Chem. Soc. Rev.* **2025**, *54*, 10326. [\[CrossRef\]](#) [\[PubMed\]](#)
12. Zhang, Y.-F.; Yin, Y.-K.; Zhang, H.; Han, Y.-F. Metal *N*-heterocyclic carbene complexes as potential metallodrugs in antitumor therapy. *Coord. Chem. Rev.* **2024**, *514*, 215941. [\[CrossRef\]](#)
13. Wragg, D.; de Almeida, A.; Bonsignore, R.; Kühn, F.E.; Leoni, S.; Casini, A. On the mechanism of gold/NHC compounds binding to DNA G-quadruplexes: Combined metadynamics and biophysical methods. *Angew. Chem. Int. Ed.* **2018**, *57*, 14524–14528. [\[CrossRef\]](#) [\[PubMed\]](#)
14. Tialiou, A.; Chin, J.; Keppler, B.K.; Reithofer, M.R. Current developments of *N*-heterocyclic carbene (Au(I)/Au(III)) complexes toward cancer treatment. *Biomedicines* **2022**, *10*, 1417. [\[CrossRef\]](#)
15. Kaps, L.; Biersack, B.; Müller-Bunz, H.; Mahal, K.; Münzner, J.; Tacke, M.; Mueller, T.; Schobert, R. Gold(I)-NHC complexes of antitumoral diarylimidazoles: Structures, cellular uptake routes and anticancer activities. *J. Inorg. Biochem.* **2012**, *106*, 52–58. [\[CrossRef\]](#)
16. Muenzner, J.K.; Biersack, B.; Kalie, H.; Andronache, I.C.; Kaps, L.; Schuppan, D.; Sasse, F.; Schobert, R. Gold(I) biscarbene complexes derived from vascular-disrupting combretastatin A-4 address different targets and show antimetastatic potential. *ChemMedChem* **2014**, *9*, 1195–1204. [\[CrossRef\]](#)
17. Hatem, E.; El Banna, N.; Heneman-Masurel, A.; Baille, D.; Vernis, L.; Riquier, S.; Golinelli-Cohen, M.-P.; Guittet, O.; Vallières, C.; Camadro, J.-M.; et al. Novel insights into redox-based mechanisms for auranofin-induced rapid cancer cell death. *Cancers* **2022**, *14*, 4864. [\[CrossRef\]](#)
18. Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J. Clin.* **2021**, *71*, 209–249. [\[CrossRef\]](#)
19. Xu, Q.L.; Li, H.; Zhu, Y.J.; Xu, G. The treatments and postoperative complications of esophageal cancer: A review. *J. Cardiothorac. Surg.* **2020**, *15*, 163. [\[CrossRef\]](#)
20. Patel, N.; Benipal, B. Incidence of esophageal cancer in the United States from 2001–2015: A United States cancer statistics analysis of 50 states. *Cureus* **2018**, *10*, e3709. [\[CrossRef\]](#)
21. Blot, W.J.; Tarone, R.E. Esophageal Cancer. In *Cancer Epidemiology and Prevention*, 4th ed.; Thun, M., Linet, M.S., Cerhan, J.R., Haiman, C.A., Schottenfeld, D., Eds.; Oxford University Press: New York, NY, USA, 2017; pp. 579–592.
22. Wang, H.; Li, S.; Liu, T.; Chen, J.; Dang, J. Neoadjuvant immune checkpoint inhibitor in combination with chemotherapy or chemoradiotherapy in resectable esophageal cancer: A systematic review and meta-analysis. *Front. Immunol.* **2022**, *13*, 998620. [\[CrossRef\]](#) [\[PubMed\]](#)
23. Harris, G.J.; Turner, J.N.; Von Hoff, D.D. Growth of carcinoma of the esophagus and gastroesophageal junction in a human tumor cloning assay. *Cancer Drug Deliv.* **1986**, *3*, 273–278. [\[CrossRef\]](#) [\[PubMed\]](#)
24. Schleser, S.W.; Ghosh, H.; Hörner, G.; Seib, J.; Bhattacharyya, S.; Weber, B.; Schobert, R.; Dandawate, P.; Biersack, B. New 4,5-diarylimidazol-2-ylidene iodidogold(I) complexes with high activity against esophageal adenocarcinoma cells. *Int. J. Mol. Sci.* **2023**, *24*, 5738. [\[CrossRef\]](#) [\[PubMed\]](#)
25. Muenzner, J.K.; Rehm, T.; Biersack, B.; Casini, A.; de Graaf, I.A.M.; Worawutputtpong, P.; Noor, A.; Kempe, R.; Brabec, V.; Kasparkova, J.; et al. Adjusting the DNA interaction and anticancer activity of Pt(II) *N*-heterocyclic carbene complexes by steric shielding of the *trans* leaving group. *J. Med. Chem.* **2015**, *58*, 6283–6292. [\[CrossRef\]](#)
26. Wang, L.; Woods, K.W.; Li, Q.; Barr, K.J.; McCroskey, R.W.; Hannick, S.M.; Gherke, L.; Credo, R.B.; Hui, Y.-H.; Marsh, K.; et al. Potent, orally active heterocycle-based combretastatin A-4 analogues: Synthesis, structure-activity relationship, pharmacokinetics, and in vivo antitumor activity evaluation. *J. Med. Chem.* **2002**, *45*, 1697–1711. [\[CrossRef\]](#)
27. Jahnke, M.C.; Hahn, F.E. Synthesis and coordination chemistry of silver(I), gold(I) and gold(III) complexes with picoline-functionalized benzimidazolin-2-ylidene ligands. *Z. Naturforsch.* **2021**, *76*, 463–473. [\[CrossRef\]](#)
28. de Marco, R.; dal Grande, M.; Baron, M.; Orian, L.; Graiff, C.; Achard, T.; Bellemin-Laponnaz, S.; Pöthig, A.; Tubaro, C. Synthesis, structural characterization and antiproliferative activity of gold(I) and gold(III) complexes bearing thioether-functionalized *N*-heterocyclic carbenes. *Eur. J. Inorg. Chem.* **2021**, *2021*, 4196–4206. [\[CrossRef\]](#)

29. Zou, P.; Chen, M.; Ji, J.; Chen, W.; Chen, X.; Ying, S.; Zhang, J.; Zhang, Z.; Liu, Z.; Yang, S.; et al. Auranofin induces apoptosis by ROS-mediated ER stress and mitochondrial dysfunction and displayed synergistic lethality with piperlongumine in gastric cancer. *Oncotarget* **2015**, *6*, 36505–36521. [\[CrossRef\]](#)
30. Fiskus, W.; Saba, N.; Shen, M.; Ghias, M.; Liu, J.; Gupta, S.D.; Chauhan, L.; Rao, R.; Gunewardena, S.; Schorno, K.; et al. Auranofin induces lethal oxidative and endoplasmic reticulum stress and exerts potent preclinical activity against chronic lymphocytic leukemia. *Cancer Res.* **2014**, *74*, 2520–2532. [\[CrossRef\]](#)
31. Muenzner, J.K.; Biersack, B.; Albrecht, A.; Rehm, T.; Lacher, U.; Milius, W.; Casini, A.; Zhang, J.-J.; Ott, I.; Brabec, V.; et al. Ferrocenyl-coupled *N*-heterocyclic carbene complexes of gold(I): A successful approach to multinuclear anticancer drugs. *Chem. Eur. J.* **2016**, *22*, 18953–18962. [\[CrossRef\]](#)
32. Bian, M.; Fan, R.; Jiang, G.; Wang, Y.; Lu, Y.; Liu, W. Halo and pseudohalo gold(I)-NHC complexes derived from 4,5 diarylimidazoles with excellent in vitro and in vivo anticancer activities against HCC. *J. Med. Chem.* **2020**, *63*, 9197–9211. [\[CrossRef\]](#) [\[PubMed\]](#)
33. Tong, Z.; Chatterjee, D.; Deng, D.; Veeranki, O.; Mejia, A.; Ajani, J.A.; Hofstetter, W.; Lin, S.; Guha, S.; Kopetz, S.; et al. Antitumor effects of cyclin dependent kinase 9 inhibition in esophageal adenocarcinoma. *Oncotarget* **2017**, *8*, 28696–28710. [\[CrossRef\]](#) [\[PubMed\]](#)
34. Vangamudi, B.; Zhu, S.; Soutto, M.; Belkhir, A.; El-Rifai, W. Regulation of β -catenin by t-DARPP in upper gastrointestinal cancer cells. *Mol. Cancer* **2011**, *10*, 32. [\[CrossRef\]](#)
35. Montalto, F.I.; De Amicis, F. Cyclin D1 in cancer: A molecular connection for cell cycle control, adhesion and invasion in tumor and stroma. *Cells* **2020**, *9*, 2648. [\[CrossRef\]](#) [\[PubMed\]](#)
36. Taylor, C.; Loomans, H.A.; Le Bras, G.F.; Koumangoye, R.B.; Romero-Morales, A.I.; Quast, L.L.; Zaika, A.I.; El-Rifai, W.; Andl, T.; Andl, C.D. Activin a signaling regulates cell invasion and proliferation in esophageal adenocarcinoma. *Oncotarget* **2015**, *6*, 34228–34244. [\[CrossRef\]](#)
37. Wang, L.; Jin, J.Q.; Zhou, Y.; Tian, Z.; Jablons, D.M.; He, B. Gli is activated and promotes epithelial-mesenchymal transition in human esophageal adenocarcinoma. *Oncotarget* **2018**, *9*, 853–865. [\[CrossRef\]](#)
38. Ahrens, T.D.; Timme, S.; Ostendorp, J.; Bogatyreva, L.; Hoepfner, J.; Hopt, U.T.; Hauschke, D.; Werner, M.; Lassmann, S. Response of esophageal cancer cells to epigenetic inhibitors is mediated via altered thioredoxin activity. *Lab. Investig.* **2016**, *96*, 307–316. [\[CrossRef\]](#)
39. Feingold, P.L.; Surman, D.R.; Brown, K.; Xu, Y.; McDuffie, L.A.; Shukla, V.; Reardon, E.S.; Crooks, D.R.; Trepel, J.B.; Lee, S.; et al. Induction of thioredoxin-interacting protein by a histone deacetylase inhibitor, entinostat, is associated with DNA damage and apoptosis in esophageal adenocarcinoma. *Mol. Cancer Ther.* **2018**, *17*, 2013–2023. [\[CrossRef\]](#)
40. Yu, X.; Zhou, Y.; Ma, X.; Zhang, W.; Li, F.; Jiang, F.; Wang, Y.; Zhang, Q.; Liu, W. Erlotinib-gold(I) complex induces leukemia cell DC differentiation and remodels the immunosuppressive microenvironment. *J. Med. Chem.* **2024**, *67*, 21795–21810. [\[CrossRef\]](#)
41. Wang, Z.; Wang, M.; Chen, Q.; Wang, M.; Li, F.; Lv, L.; Wen, Z.; Xu, Z.; Yang, Y.; Bi, C.; et al. Glabridin-gold(I) complex as a novel immunomodulatory agent targeting TrxR and MAPK pathways for synergistic enhancement of antitumor immunity. *Adv. Sci.* **2025**, *12*, e04729. [\[CrossRef\]](#)
42. Li, F.; Wen, Z.; Wu, C.; Yang, Z.; Wang, Z.; Diao, W.; Chen, D.; Xu, Z.; Lu, Y.; Liu, W. Simultaneous activation of immunogenic cell death and cGAS-STING pathway by liver- and mitochondria-targeted gold(I) complexes for chemoimmunotherapy of hepatocellular carcinoma. *J. Med. Chem.* **2024**, *67*, 1982–2003. [\[CrossRef\]](#)
43. Lu, Q.; Shan, M.; Yang, J.; Xu, Z.; Lei, Y.; Liu, W. A dinuclear gold(I) complex with bis(*N*-heterocyclic carbene) ligands potentiated immune responses against liver cancer via ROS-driven endoplasmic reticulum stress and ferroptosis. *Chin. Chem. Lett.* **2025**, *36*, 110940. [\[CrossRef\]](#)
44. Landegren, U. Measurement of cell numbers by means of the endogenous enzyme hexosaminidase. Applications to detection of lymphokines and cell surface antigens. *J. Immunol. Methods* **1984**, *67*, 379–388. [\[CrossRef\]](#)
45. Ghosh, H.; Bhattacharyya, S.; Schobert, R.; Dandawate, P.; Biersack, B. Fluorinated and *N*-acryloyl-modified 3,5-di[(*E*)-benzylidene]piperidin-4-one curcuminoids for the treatment of pancreatic carcinoma. *Pharmaceutics* **2023**, *15*, 1921. [\[CrossRef\]](#)
46. Dandawate, P.; Subramaniam, D.; Panovich, P.; Standing, D.; Krishnamachary, B.; Kaushik, G.; Thomas, S.M.; Dhar, A.; Weir, S.J.; Jensen, R.A.; et al. Cucurbitacin B and I inhibits colon cancer growth by targeting the Notch signaling pathway. *Sci. Rep.* **2020**, *10*, 1290. [\[CrossRef\]](#)
47. Gollowitzer, A.; Pein, H.; Rao, Z.; Walzl, L.; Bereuter, L.; Loeser, K.; Meyer, T.; Jafari, V.; Witt, F.; Winkler, R.; et al. Attenuated growth factor signaling during cell death initiation sensitizes membranes towards peroxidation. *Nat. Commun.* **2025**, *16*, 1774. [\[CrossRef\]](#)

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.